Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Elevated Plasma GDF-15 Levels are Associated with the Immune Non-Responder Phenotype in People with HIV

  • López López, Aida
  • Alonso Domínguez, Jacobo
  • Martínez Barros, Inés
  • Pérez González, Alexandre
  • Ocampo, Antonio
  • Morano, Luis
  • Martínez López de Castro, Noemí
  • Bisbal Pardo, Otilia
  • Díez, Cristina
  • Arcos-Rueda, Maria del Mar
  • Álvarez-Rodríguez, Ignacio
  • Portilla-Tamarit, Irene
  • Bernal-Morell, Enrique
  • López Cortés, Luis
  • Ruiz-Mateos, Ezequiel
  • Poveda, Eva
  • CoRIS cohort
  • Portilla-Tamarit, Irene|||/items/341962ea-60c0-459e-9454-90e3f9b71000
Introduction: Most people with HIV (PWH) achieve immune recovery with antiretroviral therapy (ART); however, a clinically relevant subset, known as immune non-responders (INRs), fails to restore CD4+ T-cell counts despite sustained virological suppression and shows persistent immune dysfunction. Growth differentiation factor 15 (GDF-15), a stress-responsive cytokine associated with inflammation, aging, chronic disease, and multimorbidity, has not been characterized across distinct HIV viro-immunological phenotypes. Methods: We conducted an exploratory cross-sectional study including 80 PWH classified as ART-naïve individuals, virally suppressed INRs, elite controllers (ECs), and ART-treated immune responders (IRs), as well as 20 HIV-negative controls. Plasma GDF-15 levels were measured by immunoassay. Associations with log-transformed GDF-15 concentrations were assessed using multivariable linear regression including age, CD4+ T-cell nadir, and INR status. Results: INRs showed the highest plasma GDF-15 levels (median, 1143.9 pg/ml), significantly exceeding those observed in ART-naïve individuals, ECs, IRs, and HIV-negative controls (all p ≤ 0.002). GDF-15 levels correlated positively with age, time since HIV diagnosis, and ART duration, and inversely with CD4+ T-cell nadir and the CD4/CD8 ratio (all p ≤ 0.001). In adjusted analysis, INR status remained independently associated with higher log-transformed GDF-15 levels (β = 0.271, 95% CI 0.062–0.480; p = 0.012), corresponding to 31.1% higher GDF-15 concentrations relative to non-INR participants. Conclusion: Plasma GDF-15 levels were higher in virally suppressed INRs than in other viro-immunological groups and remained independently associated with INR status after adjustment for selected covariates. These findings support further investigation of GDF-15 as a potential biomarker of incomplete immune recovery and residual biological stress in virally suppressed PWH. Prospective studies are warranted to validate its clinical and pathophysiological relevance.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Fibroblast Growth Factor 23 and Outcomes in Acute Heart Failure

  • Martí-Martínez, Arancha
  • Nuñez, Julio
  • López-Escribano, Herminio
  • de la Espriella, Rafael
  • Santas, Enrique
  • Rodríguez Borja, Enrique
  • Miró, Òscar
  • Llorens, Pere
  • Alquézar-Arbé, Aitor
  • Herrero-Puente, Pablo
  • Llorens, Pere|||/items/757956aa-c39c-4e15-850b-e5bf9ed72f94
Worsening heart failure (WHF) is a complex clinical syndrome associated with a high risk of mortality and further decompensations, characterized by fluid overload and upregulated inflammatory and fibrotic processes linked to organ dysfunction. Fibroblast growth factor 23 (FGF23) is an emerging proxy of fibrosis and may interact to influence long-term outcomes in WHF patients. This study evaluated the association between FGF23 levels and long-term outcomes in patients with WHF evaluated in the emergency department (ED). A total of 635 patients from the EAHFE registry, enrolled during 2007, 2009, and 2011, were prospectively included. FGF23 was measured in the first blood sample obtained at ED presentation. During a median follow-up of 380 days (interquartile range: 126 to 456), all-cause mortality occurred in 216 patients (34.0%), while 351 patients (55.3%) experienced the composite endpoint of death/WHF ED reconsultation and 295 (46.5%) experienced death/HF hospitalization. Event rates increased progressively across FGF23 levels. Patients with FGF23 above the median (48.4 pg/mL) displayed higher rates (per 100 patient-years) of all-cause mortality (49 vs. 31, p = 0.003), death/WHF ED reconsultation (93 vs. 65, p = 0.003), and death/HF hospitalization (77 vs. 56, p = 0.043). In continuous analyses, each doubling of FGF23 remained significantly associated with an increased risk of all three outcomes after multivariable adjustment. These associations were consistent across clinically relevant subgroups, including those defined by age, sex, and kidney function, supporting the potential prognostic value of FGF23 within this cohort, although external validation is warranted.